OCULAR THERAPEUTIX, INC Logo

OCULAR THERAPEUTIX, INC

Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.

OCUL | NDAQ

Overview

Corporate Details

ISIN(s):
US67576A1007
LEI:
Country:
United States of America
Address:
15 CROSBY DRIVE, 1730 BEDFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company is committed to redefining the treatment experience for patients with retinal diseases by aiming to reduce the therapeutic burden associated with current standards of care. Its core focus is on its proprietary hydrogel-based drug delivery technology. The lead product candidate, AXPAXLI™ (axitinib intravitreal hydrogel), is an investigational therapy in late-stage clinical development for the treatment of wet age-related macular degeneration (wet AMD). Ocular Therapeutix's pipeline also extends to other ophthalmic conditions, including glaucoma and ocular hypertension.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:25
Quarterly Report
10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
English 1.5 MB
2025-11-04 13:19
Regulatory News Service
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
English 177.7 KB

Automate Your Workflow. Get a real-time feed of all OCULAR THERAPEUTIX, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OCULAR THERAPEUTIX, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OCULAR THERAPEUTIX, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America AGIO
AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America ALGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.